[1] Choi H, Cho SY, Schwartz RH. Dual effects of Sprouty 1 on TCR signaling depending on the differentiation state of the T cell. J Immunol,2006, 176: 6034-6045.
[2] Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol, 2019, 234: 8509-8521.
[3] Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res, 2017, 126:97-108.
[4] Park H, Jung JH, Jung MK,at al.Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.Hepatol Int, 2020, 14: 249-258.
[5] Safarzadeh E, Orangi M, Mohammadi H, et al. Myeloid-derived suppressor cells. Important contributors to tumor progression and metastasis. J cell physiol, 2018, 233: 3024-3036.
[6] Lu LC, Chang CJ, Hsu Ch. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma:current state and future perspectives. J hepatocell carcinoma, 2019, 6: 71-84.
[7] Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res,2018, 24: 1518-1524.
[8] Liu Z, Song Z, Sun J, et al. Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility. Int J Clin Exp Pathol, 2018, 8: 15112-15118.
[9] Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother, 2019, 68: 599-608.
[10] Izzedine H, Mateus C, Boutro C. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant, 2017, 32: 936-942.
[11] Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma:implications for genomic and immune therapies.Mol cancer, 2017, 16: 149.
[12] Xu F, Jin T, Zhu Y, et al. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res, 2018, 37: 110.
[13] Huard B, Mastrangeli R, Prigent P Bruniquel, et al. Characterization of the major histocompatibility complex class Ⅱ binding site on LAG-3 protein. Proc Nati Acad Sci USA, 1997, 94: 5744-5749.
[14] Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell, 2018, 176: 334-347.
[15] Yamamoto T, Gotoh M, Sasaki H, et al. Molecular cloning and initial characterization of a novel fibrinogenrelated gene, HFREP-1. Biochem Biophys Res Commun, 1993, 193: 681-687.
[16] Yarchoan M, Xing D, Luan L, et al. Characterization of the Immuune microenvironment in hepatocellular carcinoma. Clin Cancer Res, 2017, 23: 7333-7339.
[17] Gaglian N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cell. Nat Med, 2013, 19: 739-746.
[18] Rotte A, Jin JY, Lemaire V. Mechanistic cover view of immune checkpoint to support the rational design of their combination of cancer immunotherapy. Ann Oncel, 2008, 29: 71-83.
[19] Li Z, Li N, Li F, et al. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissue and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine, 2016, 95: e5749.
[20] Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. Haematologica, 2018, 11: 126.
[21] Zhang H, Song Y, Yang H, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappaB/IL-6/STAT3 axis. Oncogene, 2018, 27:2456-2468.
[22] Dardalhon V, Anderson AC, Kaeman J, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 2010, 185: 1383-1392.
[23] Liu F, Zeng J, Zhou S, et al. Blocking TIM-3 or/and PD-1 reverses dysfunction of tumor-infiltrating in HBV-related hepatocellular carcinoma. Cancer, 2018, 105: 439-501.
[24] Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cells IFN-gamma-mediated antitumor or immunity and suppress established tumors. Cancer Res, 2017, 71: 3540-3551.
[25] Gefen T, Castrol I, Muharemagic D, et al. A TIM-3 oligonucleotide aptamer enhances T cells functions and potentiates tumor immunity in mice. Mol Ther, 2017, 25: 2280-2288. |
